32 completed, 10 unknown, 6 terminated, 3 withdrawn. 14 Phase 2, 13 Phase 1, 11 Not applicable, 8 Phase 3, 8 Phase 4.
Follow this drug Literature Review of Scopolamine trials Research Report on Scopolamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Representation of Spatiotemporal Information in Human Episodic Memory and Navigation Scopolamine - Scopolamine or Placebo, Schema to Organize Memory or no Schema | Early Phase 1 | Enrolling by invitation | University of Arizona | 15 | 2025-04-01 | 2026-04-30 |
| PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor Scopolamine, [11C]EMO ([11C]LSN3172176) - Muscarinic Receptor Occupancy | Phase 1 | Withdrawn | Yale University | 2025-03-01 | 2025-05-11 | |
| Efficacy and Safety of Escócia Association in the Treatment of Acute Pain Escócia association, Placebo Ketorolac, Placebo Scopolamine - Acute Pain | Phase 2 | Withdrawn | EMS | 2023-02-01 | 2023-09-08 | |
| Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 503 | 2022-08-23 | 2023-03-21 |
| Nebulizer Delivery of Intranasal Scopolamine Scopolamine, Placebo - Scopolamine, Motion Sickness | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 14 | 2022-01-24 | 2025-08-28 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Placebo Nasal Gel - Motion Sickness, Space, Motion Sickness | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 30 | 2022-01-21 | 2024-05-17 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine) - Motion Sickness, Space, Motion Simulation | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 80 | 2021-08-10 | 2024-05-16 |
| Toward a Computationally-Informed, Personalized Treatment for Hallucinations Rivastigmine Transdermal System, Scopolamine, Placebo Patch - Hallucinations, Auditory, Psychosis | Early Phase 1 | Recruiting | Yale University | 35 | 2021-07-15 | 2025-06-05 |
| Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 140 | 2021-06-14 | 2021-09-17 |
| Scopolamine in Bipolar Depression Placebo / Saline, Scopolamine - Bipolar Disorder Depression | Phase 2 | Completed | Dr. Brian Hallahan | 55 | 2021-03-23 | 2025-04-29 |
| Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea Lumbar spine manipulation, Hyoscine and Ibuprofen - Women With Primary Dysmenorrhea | Not applicable | Completed | University of Alcala | 42 | 2021-02-28 | 2022-11-18 |
| Multimodal Analgesia Effect on Post Surgical Patient Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product - Obesity, Morbid, Surgery | Phase 4 | Completed | University of California, Davis | 60 | 2021-01-20 | 2026-09-14 |
| The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone - Amyotrophic Lateral Sclerosis, Respiratory Function | Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-11-01 | 2020-10-14 |
| Pharmacological Modulation of Brain Oscillations in Memory Processing Scopolamine (0.4mg), Placebo - Epilepsy, Seizures | Early Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2019-08-01 | 2026-10-05 |
| A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery Scopolamine Patch (Transderm V) - Post Operative Pain Management | Completed | Alexander M Spiess, MD | 74 | 2019-06-25 | 2022-09-08 | |
| Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, Placebos - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 102 | 2019-06-09 | 2019-12-03 |
| Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Scopolamine, Placebo Nasal Gel - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 98 | 2019-06-07 | 2023-05-06 |
| Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch - Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness | Phase 3 | Unknown | Naval Aeromedical Research Unit, Dayton | 320 | 2019-04-01 | 2019-04-19 |
| Scopolamine in Healthy Volunteers Scopolamine - Major Depressive Disorder (MDD) | Phase 1 | Unknown | Repurposed Therapeutics, Inc. | 130 | 2018-08-01 | 2020-02-17 |
| DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop® - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 23 | 2018-06-29 | 2020-01-07 |
Showing 20 of 54. Sign in to see all of them.
Motion Sickness (10) · Depressive Disorder, Major (4) · Vomiting (4) · Depression (3) · Nausea (3) · Agnosia (2) · Alzheimer Disease (2) · Bipolar Disorder (2) · Cognitive Dysfunction (2) · Dementia (2) · Memory Disorders (2) · Pain (2) · Postoperative Nausea and Vomiting (2) · Space Motion Sickness (2) · Acute Pain (1)
Repurposed Therapeutics, Inc. (9) · Massachusetts General Hospital (2) · Medical Corps, Israel Defense Force (2) · Pfizer (2) · Yale University (2) · Ain Shams Maternity Hospital (1) · Alexander M Spiess, MD (1) · AstraZeneca (1) · Boston University (1) · Capital Medical University (1) · Dartmouth-Hitchcock Medical Center (1) · Dr. Brian Hallahan (1) · Drexel University (1) · Drexel University College of Medicine (1) · EMS (1)
United States (33) · China (5) · Israel (2) · United Kingdom (2) · France (1) · Ireland (1) · Mexico (1) · Spain (1) · Sweden (1) · Thailand (1)
David Helton (3) · David R Helton (3) · Scott J Wood, PhD (2) · Albert Powers, MD, PhD (1) · Alexander Spiess, MD (1) · Arne Ekstrom, Ph.D. (1) · Barbara Jachniewicz, MSN, CRNFA, (1) · Brad Lega, M.D. (1) · Bradley C Lega, MD (1) · Cassandra Key, MD (1) · Cristina Cusin, M.D. (1) · David Abramson, MD (1) · David Matuskey, MD (1)
PMID 14667752, PMID 17015814, PMID 20074703, PMID 20153691, PMID 21644059, PMID 22797672, PMID 25791027, PMID 25906190, PMID 27366831, PMID 27871302, PMID 29514224, PMID 30184133, PMID 30626409, PMID 31174846, PMID 31236286, PMID 32655854, PMID 33528788, PMID 34002866, PMID 35461262, PMID 38152462, PMID 41412339
2017 (1), R01NS076856 (1), R01NS125250 (1), R21MH122940 (1)